Sertraline safety and efficacy in major depression: A double-blind fixed-dose comparison with placebo

  title={Sertraline safety and efficacy in major depression: A double-blind fixed-dose comparison with placebo},
  author={Louis F. Fabre and Faruk S. Abuzzahab and M. Amin and James L. Claghorn and Joseph Mendels and William Matthew Flinders Petrie and Sanjay Dub{\'e} and Joyce Graham Small},
  journal={Biological Psychiatry},
Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial*
No differences in efficacy were observed for fixed-dose escitalopram 10 mg/day and sertraline flexibly dosed from 50–200  mg/day, and both treatments were generally well tolerated.
A placebo-controlled, randomized withdrawal study of sertraline for major depressive disorder in Japan
Results confirm the efficacy of sertraline in preventing the relapse of MDD in Japanese patients and mean changes from beginning to end of the double-blind phase on measure of depressive symptoms, quality of life and global improvement also significantly favoured sERTraline over placebo.
Dose–response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder
In this assessment of patients with MDD, the HAM-D6 was shown to be more sensitive compared with theHAM-D17 at detecting treatment effects, and findings support that duloxetine 60 mg daily is the best effective dose.
The antidepressant effect of sertraline is not enhanced by dose titration: results from an outpatient clinical trial
The results suggest that for most patients continued treatment with 50 mg dose of sertraline yields a rate of antidepressant response that is comparable to what is achieved by dose escalation from 50 mg to 150 mg of sERTraline after 3 weeks of treatment.
An Open Study of Sertraline in Acute and Continuation Treatment of Depressed Out-Patients
The results of this open study are consistent with those of controlled studies in which sertraline was effective and well tolerated, in acute and continuation treatment for major depression, at 50 mg/day in most patients.
Efficacy between sertraline GPO and the original drug in treatment of major depressive disorder
There were no differences in efficacy between sertraline GPO and the original drug in treatment of major depressive disorder and there were some limitations of this study.
Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder.
The results of the current study suggest that sertraline is a safe, well-tolerated, and significantly effective treatment for PTSD.
A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression
Both sertraline and moclobemide improved the symptoms of atypical depression in this study and were well tolerated.


Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression.
The amitriptyline group showed a higher proportion of anticholinergic and sedative side effects and dizziness compared with patients who received either sertraline or placebo, and showed a significantly greater improvement from baseline than the placebo group.
A fixed-dose clinical trial of fluoxetine in outpatients with major depression.
The 20-mg dose produced improvement of depression in the moderate-severe depression group as expressed in significant reductions of scores on the Hamilton Rating Scale for Depression and the Patient Global Impressions scale.
Double‐blind dose determination study of a new antidepressant—sertraline
The efficacy of sertraline could not be demonstrated under these design constraints, although differential dose level effects were indicated and doses up to 100 mg/day would appear to be more clinically appropriate than higher dosage levels.
Effects of antidepressant medication on sexual function: a controlled study.
Antidepressant-related sexual dysfunction may be of clinical importance for medication compliance in view of current recommendations that antidepressants be administered for longer periods as maintenance therapy or for prophylaxis.
Optimal dose regimen for paroxetine.
The dose regimen for paroxetine in the treatment of depression has been well established through a number of individual dosing studies and analyses from the worldwide clinical data base. The starting
Clinical overview of serotonin reuptake inhibitors.
Serotonin reuptake inhibitors have not replaced the tricyclics, but are a useful addition to the variety of drugs currently used for the treatment of depression.
Psychotropic drug induced weight gain: mechanisms and management.
Evidence suggests that compounds, which either antagonize or downregulate serotonin receptors, are more likely to stimulate carbohydrate hunger and weight gain, and Amitriptyline, chlorpromazine, mesoridazines, thioridazine, and lithium are most likely to produce weight gain.
The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor.
This pharmacologic and pharmacokinetic profile, taken together with extensive clinical data, indicates that paroxetine is a valuable addition to the physician's armamentarium for the treatment of depression.
Neuroleptic treatment in the borderline patient: advantages and techniques.
  • P. Soloff
  • Psychology
    The Journal of clinical psychiatry
  • 1987
A low-dose neuroleptic strategy is indicated in borderline personality disorder as an acute treatment for symptoms of anger, hostility and suspiciousness, referential thinking and paranoid ideation,
Antidepressants : neurochemical, behavioral, and clinical perspectives
This volume is noteworthy in that it does provide the salient biological and psychological knowledge currently available to advance hypotheses for further study, and provides important data for the clinical application of ECT.